Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow AN2 Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for AN2 Therapeutics, Inc.

ANTX

AN2 Therapeutics, Inc.

About AN2 Therapeutics, Inc.

AN2 Therapeutics, Inc. is a biopharmaceutical company specializing in novel small molecule therapeutics derived from boron chemistry. Its lead candidate, epetraborole, targets treatment-refractory non-tuberculous mycobacterial lung disease, addressing a significant unmet need. With a focus on infectious diseases and oncology, AN2 is advancing multiple programs, including a partnership with the Bill and Melinda Gates Foundation for tuberculosis and malaria treatments, leveraging non-dilutive funding for global health initiatives.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from AN2 Therapeutics, Inc.

1
1
AN2 Therapeutics, Inc. AN2 Therapeutics Reports Q1 2026 Financial Results with $10M Net Loss and Increased Cash Position

Via official filing (AI summary) | 24 days ago | 0 comments

2
1
AN2 Therapeutics, Inc. AN2 Therapeutics Reports $35.2 Million Net Loss for 2025, Advances Product Pipeline

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
AN2 Therapeutics, Inc. AN2 Therapeutics Reports Q3 2025 Financial Results with Reduced Net Loss

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
AN2 Therapeutics, Inc. AN2 Therapeutics Reports 55% Decrease in Net Losses for Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
AN2 Therapeutics, Inc. AN2 Therapeutics Reports Improved Net Loss of $10.6 Million in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
AN2 Therapeutics, Inc. AN2 Therapeutics Reports $51.3 Million Net Loss for Fiscal Year 2024, Restructures Workforce

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
AN2 Therapeutics, Inc. AN2 Therapeutics Reports Improved Financials, Restructuring, and Clinical Trial Plans

Via official filing (AI summary) | over 1 year ago | 0 comments